About Chromadex Corp. 
Chromadex Corp.
Pharmaceuticals & Biotechnology
Chromadex Corporation is an integrated nutraceutical company. The Company and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provides research and quality-control products and services to the natural products industry. The Company partners with universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of nicotinamide adenine dinucleotide (NAD) and its impact on human health. The Company’s operated segments are: Consumer Product, Ingredients, and Analytical Reference Standards and Service Segment. Its Consumer Product segment offers TRU NIAGEN to consumers worldwide. Its ingredients business segment develops and commercializes ingredients, including nicotinamide riboside (NR), for which its brand name is NIAGEN. It also develops pterostilbene, which is marketed and sold under its brand name, pTeroPure.
Company Coordinates 
Company Details
10900 Wilshire Blvd Ste 600 , LOS ANGELES CA : 90024-6534
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 33 Schemes (10.66%)
Foreign Institutions
Held by 33 Foreign Institutions (3.68%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. Frank Jaksch
Executive Chairman of the Board
Mr. Robert Fried
Chief Executive Officer, Director
Mr. Kurt Gustafson
Lead Independent Director
Mr. Jeffrey Baxter
Independent Director
Mr. Stephen Block
Independent Director
Mr. Tony Lau
Independent Director
Mr. Steven Rubin
Independent Director
Revenue and Profits:
Net Sales:
31 Million
(Quarterly Results - Jun 2025)
Net Profit:
4 Million
Pharmaceuticals & Biotechnology
USD 754 Million (Micro Cap)
63.00
NA
0.00%
-0.93
29.49%
11.74






